secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0000950170-22-001969
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q4 2021 net loss $55.6M; cash $735M plus $200M from GSK; pipeline advancing
--------------------------------------------------------------------------------

- Net loss Q4 2021 $55.6M ($0.68/share) vs $52.2M ($0.66) in Q4 2020; full-year net loss $36.3M ($0.45) vs $190.2M ($2.45).
- Collaboration revenue Q4 $14.0M (up from $4.9M); full-year $207.1M (up from $21.1M) driven by GSK deal.
- Cash $735.3M at Dec 31, 2021; plus $200M from GSK in Jan 2022. Cash runway expected into mid-2024.
- AL002 Phase 2 ARIA observed; protocol amended to exclude APOE e4/e4 homozygotes.
- Appointed Sara Kenkare-Mitra (President/Head R&D) and Marc Grasso (CFO).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017022001969/0000950170-22-001969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017022001969/alec-20220224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-001969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer